(Q40886376)

24 September 2017

1 reference

title

Loracarbef: a new orally administered carbacephem antibiotic (English)

1 reference

24 September 2017

1 reference

ChEBI release 2020-05-28

R W Force

1

1 reference

24 September 2017

M C Nahata

series ordinal

2

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 March 1993

1 reference

Annals of Pharmacotherapy

24 September 2017

published in

1 reference

24 September 2017

volume

27

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

321-329

1 reference

In vitro susceptibilities of common pediatric pathogens to LY163892.

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

In vitro activities of LY163892, cefaclor, and cefuroxime

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Comparative in-vitro activity of a new oral carbacephem, LY163892.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Antimicrobial activity of LY163892, an orally administered 1-carbacephem

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

In vitro activity of LY163892 against pathogens isolated from pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

In-vitro activity and beta-lactamase stability of LY163892.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

In vitro activity and beta-lactamase stability of LY163892.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Susceptibility of new beta-lactams to the expanded-spectrum beta-lactamase CTX-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Pharmacokinetic profile of loracarbef

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Pharmacokinetics of LY163892 in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Loracarbef concentrations in middle ear fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Loracarbef versus cefaclor in the treatment of urinary tract infections in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Management of the patient with allergic reactions to antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

Effect of loracarbef on the normal oropharyngeal and intestinal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302700315

10.1177/106002809302700315

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference